Trade Names:Heparin Sodium- Injection 1,000 units/mL- Injection 2,000 units/mL- Injection 2,500 units/mL- Injection 5,000 units/mL- Injection 10,000 units/mL- Injection 20,000 units/mL- Injection 40,000 units/mL
Trade Names:Hep-Lock- Injection 10 units/mL- Injection 100 units/mL
Trade Names:Hep-Lock U/P- Injection 10 units/mL- Injection 100 units/mLHepalean (Canada)Hepalean-Lok (Canada)Heparin Leo (Canada)
Inhibits reactions that lead to clotting.
Heparin sodium is not absorbed from GI; must be given IV or subcutaneous. T max is 2 to 4 h (subcutaneous).
Distribution is controlled by the liver; distributed in plasma and is extensively and nonspecifically protein bound.
The liver and the reticuloendothelial system are the sites of biotransformation.
The average t 1/ 2 is 30 to 180 min, and is dose-dependent and non-linear. Up to 50% is excreted in urine as unchanged.Hemodialysis
Heparin is not removed.
Onset is immediate (IV) and 20 to 60 min (subcutaneous).
The t 1/ 2 may be increased.Hepatic Function Impairment
The t 1/ 2 may be increased.Infection/malignancy/pulmonary embolism
The t 1/ 2 may be decreased.Obesity
The t 1/ 2 may be increased.
Prophylaxis and treatment of venous thrombosis and its extensions, pulmonary embolism (PE), peripheral arterial embolism, and atrial fibrillation with embolization; diagnosis and treatment of acute and chronic consumption coagulopathies (DIC); prevention of postoperative deep venous thrombosis (DVT), and PE.
Prophylaxis of left ventricular thrombi and cerebrovascular accidents post-MI; treatment of myocardial ischemia; prevention of cerebral thrombosis in evolving strokes; adjunctive treatment of coronary occlusion with acute MI.
Severe thrombocytopenia; uncontrolled bleeding (except because of DIC); patients in whom suitable blood coagulation tests cannot be performed.
Subcutaneous 10,000 to 20,000 unit as initial dose followed by 8000 to 20,000 unit every 8 to 12 h. Intermittent IV 10,000 unit as initial dose followed by 5,000 to 10,000 unit every 4 to 6 h. IV infusion 20,000 to 40,000 unit/day.Children
Intermittent IV 50 unit/kg as initial dose followed by 100 unit/kg every 4 h. IV infusion 50 unit/kg as initial dose followed by 20,000 unit/m 2 /24 h.Low-dose Prophylaxis
Subcutaneous 5,000 unit 2 h before surgery and every 8 to 12 h thereafter for 7 days or until patient is fully ambulatory, whichever is longer.Surgery of Heart and Blood VesselsAdults
300 to 400 unit/kg.Blood Transfusion
Add 400 to 600 unit/100 mL of whole blood.Clearing Intermittent Infusion Sets
10 to 100 unit/mL.Laboratory Samples
Add 70 to 150 unit/10 to 20 mL of whole blood.
Store at room temperature. Protect from freezing.
May cause increased risk of bleeding.
Heparin is acidic and incompatible with many drugs.
Drug causes increased concentrations.
Necrosis; transient alopecia; urticaria.
Hypersensitivity (chills, fever, urticaria, asthma, rhinitis, lacrimation, headache, nausea, vomiting, shock); anaphylactoid reactions; allergic vasospastic reactions, including painful ischemia, cyanotic limbs; osteoporosis; priapism; rebound hyperlipidemia on discontinuation.
Category C .
Not excreted in breast milk.
Higher incidence of bleeding in women older than 60 yr of age.
Generalized hypersensitivity can occur. Reactions range from mild to severe.
Benzyl alcohol, used as preservative in some products, is associated with a fatal gasping syndrome in premature infants.
Higher incidence of bleeding in women older than 60 yr.
Hemorrhage can occur at virtually any site. Use heparin with extreme caution in patients at increased risk of hemorrhage.
Heparin administration may cause hyperlipidemia in patients with dysbetalipoproteinemia (type III).
Avoid IM use because of local irritation, erythema, pain, hematoma, or ulceration.
Bleeding, nosebleeds, hematuria, tarry stools, easy bruising, or petechiae.
Copyright © 2009 Wolters Kluwer Health.